Nuclera Funding: $145M Raised, Series C (2026)

Nuclera funding overview

Nuclera is based in Cambridge, UK. Nuclera has raised $145M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in January 2026. The round record for Nuclera runs through 2026; nothing later has been disclosed. Investors on record include Elevage Medical Technologies, Patient Square Capital, British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, GK Goh and 10 others. 16 distinct backers are named across the disclosed rounds.

Nuclera at a glance

Total raised: $145M
Latest round: Series C
Latest round date: January 2026
Headquarters: Cambridge, UK
Notable investors: Elevage Medical Technologies, Patient Square Capital, British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, GK Goh, M&G Catalyst, E Ink Holdings

Frequently asked about Nuclera funding

How much has Nuclera raised?: Nuclera has raised $145M in total disclosed funding across the rounds on record.
Who has invested in Nuclera?: Elevage Medical Technologies, Patient Square Capital, British Patient Capital, Cambridge Innovation Capital, Jonathan Milner, GK Goh are named among the investors backing Nuclera.
What was the latest Nuclera funding round?: The most recent disclosed round is a Series C, announced in January 2026.
Where is Nuclera based?: Nuclera is based in Cambridge, UK.
When did Nuclera last raise?: The last disclosed Nuclera round closed in January 2026 at Series C.

We update the Nuclera record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Cambridge and their backers are listed below.

Nuclera Funding: $145M Raised, Series C (2026)

Nuclera funding overview

Nuclera at a glance

Frequently asked about Nuclera funding

Companies related to Nuclera (26)

Browse related funding lists (9)